Docoh
Loading...

PYPD Polypid

PolyPid Ltd. is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

PYPD stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Mar 21
16 Oct 21
31 Dec 21
Quarter (USD)
Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Polypid earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

15.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 23 21 +9.5%
Opened positions 5 3 +66.7%
Closed positions 3 2 +50.0%
Increased positions 8 9 -11.1%
Reduced positions 6 4 +50.0%
13F shares
Current Prev Q Change
Total value 27.13M 41.72M -35.0%
Total shares 2.88M 2.84M +1.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Gabriel Capital Management 1.24M $12.26M 0.0%
ARK Investment Management 605.38K $5.48M +4.8%
Moore Capital Management 281.98K $2.55M -0.5%
Silverarc Capital Management 154.57K $1.4M +3.2%
UBS UBS Group AG - Registered Shares 154.16K $1.4M +1.8%
Victory Capital Management 111.62K $1.01M -4.8%
Alliancebernstein 100K $906K 0.0%
Millennium Management 56.53K $512K +153.5%
IVZ Invesco 24.12K $218K -71.5%
JPM JPMorgan Chase & Co. 20.83K $189K -3.7%
Largest transactions
Shares Bought/sold Change
IVZ Invesco 24.12K -60.46K -71.5%
Millennium Management 56.53K +34.23K +153.5%
ARK Investment Management 605.38K +27.64K +4.8%
Renaissance Technologies 19.19K +19.19K NEW
Two Sigma Investments 0 -15.04K EXIT
Meitav Dash Investments 14.5K +14.5K NEW
FHI Federated Hermes 18.19K -12.13K -40.0%
Cresset Asset Management 11.72K +11.72K NEW
Geode Capital Management 11.18K +11.18K NEW
Victory Capital Management 111.62K -5.59K -4.8%

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg

Proxies

No filings

Patents

APP
Utility
Sustained-release Drug Carrier Composition
16 Sep 20
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer.
GRANT
Utility
Methods for the treatment of peri-implantitis
31 Aug 20
The present invention relates to pharmaceutical compositions and methods for the treatment of peri-implant diseases, in particular peri-implant disease characterized by the destruction of the crest of the alveolar bone supporting the implant.
APP
Utility
Compositions and Methods for the Treatment and Prophylaxis of Surgical Site Infections
26 Aug 20
The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.
GRANT
Utility
Sustained-release drug carrier composition
15 Jun 20
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer.
GRANT
Utility
Sustained-release drug carrier composition
4 Nov 19
The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block-co-polymers comprising a non-biodegradable polymer and a biodegradable polymer.